SEARCH

SEARCH BY CITATION

References

  • 1
    Albengres E, Pinquier JL, Riant P, Bree F, Urien S, Barre J, Tillement JP: Pharmacologic criteria for risk–benefit evaluation of NSAIDs. Scand J Rheumatol 73 (suppl): 315, 1988
  • 2
    Erikson N, Furst DE: Mechanisms of action of NSAID. Ther Drug Monit 9: 918, 1988
  • 3
    Furst DE, Paulus HE: Aspirin and other non-steroidal anti-inflammatory drugs, Arthritis and Allied Conditions. Twelfth edition. Edited by DJMcCarty, WJKoopman. Philadelphia, Lea & Febinger, 1993
  • 4
    Kitchen EA, Dawson W, Rainsford KD, Carson T: Inflammation and possible modes of action of anti-inflammatory drugs, Anti-inflammatory and Anti-rheumatic Drugs. Volume 1: Inflammation Mechanisms and Actions of Traditional Drugs. Edited by KDRainsford. Boca Raton, CRC Press, 1985
  • 5
    Preston SJ, Arnold MH, Beller IM, Broshs PM, Buchanan WW: Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid in rheumatoid arthritis. Br J Clin Pharmacol 27: 607611, 1989
  • 6
    Ku EC, Lee W, Kothari HV, Scholer DW: Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med 80 (suppl 4B): 1823, 1986
  • 7
    Abramson S, Korchas H, Ludewig R, Edelson H, Haines K, Levin RI, Herman R, Rider L, Kimmel S, Weissmann G: Modes of action of aspirin-like drugs. Proc Natl Acad Sci USA 82: 72277231, 1985
  • 8
    Abramson S, Edelson H, Kaplan H, Ludewig R, Weissmann G: Inhibition of neutrophil activation by NSAID. Am J Med 77 (suppl 4B): 36, 1984
  • 9
    Bell AL, Adamson H, Kirk F, McCaigue MD, Rotman H: Diclofenac inhibits monocyte superoxide production ex vivo in rheumatoid arthritis. Rheumatol Int 11: 2730, 1991
  • 10
    Scheja A, Forsgren A, Marsal L, Wollheim F: Inhibition of in vivo leucocyte migration by NSAIDs. Clin Exp Rheumatol 3: 5358, 1985
  • 11
    Heller LA, Ingelfinger JA, Goldman P: Non-steroidal anti-inflammatory drugs and aspirin: analyzing the scores. Pharmacotherapy 5: 3038, 1985
  • 12
    Pincus T, Callahan LF: Clinical use of multiple nonsteroidal anti-inflammatory drug preparations within individual rheumatology private practices. J Rheumatol 16: 12531258, 1989
  • 13
    Blechman WJ, Lechner BL: Clinical comparative evaluation of choline magnesium trisalicylate and acetylsalicylate in rheumatoid arthritis. Rheumatol Rehabil 18: 119124, 1979
  • 14
    Luggen ME, Gartside PS, Hess EV: NSAID in rheumatoid arthritis: duration of use as a measure of relative value. J Rheumatol 16: 15651569, 1989
  • 15
    Godfrey RG, Calabro JJ, Mills D, Maltz BA: A double-blind crossover trial of aspirin, indomethacin and phenylbutazone in ankylosing spondylitis (abstract). Arthritis Rheum 15: 110, 1972
  • 16
    Day RO, Furst DE, Dromgoole SH, Kamm B, Roe R, Paulus H: Relationship of serum naproxen concentration to efficacy in RA. Clin Pharmacol Ther 31: 733740, 1982
  • 17
    Furst DE, Caldwell JR, Klugman MP, Enthoven D, Rittweger K, Scheer R, Sarkissian E, Dromgoole S: Serum concentration and dose response relationship for carprofen in RA. Clin Pharmacol Ther 44: 186194, 1988
  • 18
    Grennan DM, Aarons L, Siddiqui M, Richards M, Thompson R, Higham C: Dose-response study with ibuprofen in RA: clinical and pharmacokinetic findings. Br J Clin Pharmacol 18: 311316, 1983
  • 19
    Bellamy N, Buchanan WW, Kean WF: Variations in responses to NSAID, Therapeutic Applications of NSAIDs: Subpopulations and New Formulations. Edited by JPFamaey, HEPaulus. New York, Marcel Dekker, 1992
  • 20
    Bradley JD, Rudy AC, Katz BP, Ryan SI, Kalasinski LA, Brater DC, Hall SD, Brandt KD: Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. J Rheumatol 19: 130134, 1992
  • 21
    Gressbinger G, Peck WS, Menzel-Soglowek S, Brune K: (R)-flurbiprofen: isomeric ballast or active entity of the racemic compound (abstract no. 14), Third World Conference on Variability in Response to Anti-Rheumatic Drugs. Singapore, July 2224, 1992
  • 22
    Lin JH, Cocchetto DM, Duggan DE: Protein binding as a primary determinant of the clinical pharmacokinetic properties of NSAID. Clin Pharmacokinet 12: 402432, 1987
  • 23
    Jamali S, MacFarlane JG, Grace EM, Kassam YB: Frequency of administration of short half-life non-steroidal anti-inflammatory analgesics (NSAIDs): studies with ibuprofen. Clin Exp Rheumatol 4: 9193, 1986
  • 24
    Brooks PM, Day RO: Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 324: 17161725, 1991
  • 25
    Jeremy JY, Williams JD: Prodrugs: the answer to NSAID-induced gastropathy? J Drug Devel 3: 93107, 1990
  • 26
    Day RO, Graham GG, Williams KM, Champion GD, De Jager J: Clinical pharmacology of NSAID. Pharmacol Ther 33: 383433, 1987
  • 27
    Verbeeck RK, Wallace SM, Loewen GR: Reduced elimination in the elderly is not necessarily due to impaired glucuronidation. Br J Clin Pharmacol 17: 783788, 1984
  • 28
    Reinberg A, Levi F, La Brecque G, Decousas H, Bruguerolle B: Clinical chronopharmacology and chronotherapeutics of NSAIDs, Therapeutic Applications of NSAIDs: Subpopulations and New Formulations. Edited by JPFamaey, HEPaulus. New York, Marcel Dekker, 1992
  • 29
    Pownall R, Pickvane NJ: The optimum interval between flurbiprofen doses: scheduling for circadian rhythms in RA. Br J Clin Practice 4: 689693, 1987
  • 30
    Furst DE: The basis for variability of response to anti-rheumatic drugs. Baillieres Clinical Rheumatol 2: 395424, 1988
  • 31
    Hansen P, Horn JR, eds. All NSAID are not alike with regard to drug interactions. Drug Interaction Newsletter 7: 711, 1987
  • 32
    Furst DE, Anderson W: Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 36: 804810, 1993
  • 33
    Soll AH, Weinstein WM, Kurata J, McCarthy D: NSAID and peptic ulcer disease. Ann Intern Med 114: 307319, 1991
  • 34
    Fries JF, Williams CA, Bloch DA, Michel BA: NSAID-associated gastropathy: incidence and risk factor models. Am J Med 91: 213221, 1991
  • 35
    Griffen MR, Piper JM, Daugherty JR, Snowden M, Ray WA: NSAID use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114: 257263, 1991
  • 36
    Gabriel SE, Jakimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of NSAID: a meta-analysis. Ann Intern Med 115: 787796, 1991
  • 37
    Kaufmann HJ, Taubin HL: NSAID activate quiescent inflammatory bowel disease. Ann Intern Med 107: 513516, 1987
  • 38
    Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI: Gastrointestinal damage associated with the use of NSAID. N Engl J Med 327: 749754, 1992
  • 39
    Garell S, Matarese RA: Renal effects of prostaglandins and clinical adverse effects of non-steroidal anti-inflammatory agents. Medicine (Baltimore) 63: 165181, 1984
  • 40
    Murray KM, Keane WR: Review of drug-induced acute interstitial nephritis. Pharmacotherapy 12: 462467, 1992
  • 41
    Ciabattoni G, Anotti GA, Pierucci A, Simoretti BM, Manzi M, Pugliesi T, Barsotti P, Pecci G, Taggi F, Patrono C: Effects of sulindac and ibuprofen in patients with chronic glomerular disease. N Engl J Med 310: 279283, 1984
  • 42
    Brater DC, Anderson SA, Brown-Cartwright D, Toto RD: Effects of NSAID on renal function in patients with renal insufficiency and in cirrhotics. Am J Kidney Dis 8: 351355, 1986
  • 43
    Ryan J, McMahan F, Vargas R, Gotzkowsky S, McNamara D, Kvam D, Heide M, Ekholm B: Effects of salsalate, aspirin and naproxen on plasma renin activity and platelet thromboxane synthesis (abstract). Arthritis Rheum 29 (suppl 4): S103, 1986
  • 44
    Abraham PA, Stillman MT: Salsalate exacerbation of chronic renal insufficiency: relation to inhibition of prostaglandin synthesis. Arch Intern Med 147: 16741676, 1987
  • 45
    Castol A, Netter P, Larrey D, Carlier P, Gaire M, Bannworth B: Hepatitis aux anti-inflammatories non-steroidiens. Therapie 43: 229233, 1988
  • 46
    Katz LM, Love PY: NSAIDs and the liver, Therapeutic Applications of NSAIDs: Subpopulations and New Formulations. Edited by JPFamaey, HEPaulus. New York, Marcel Dekker, 1992
  • 47
    Park GD, Spector R, Headsheam T, Goldberg M: Serious adverse reactions associated with sulindac. Arch Intern Med 142: 12921294, 1982
  • 48
    Purcel P, Henry D, Melville G: Diclofenac hepatitis. Gut 32: 13811385, 1991
  • 49
    International Agranulocytosis and Aplastic Anemia Study Group: Risks of agranulocytosis and aplastic anemia. JAMA 256: 17491757, 1986
  • 50
    Jacobs J, Goldstein AG, Kelly ME, Bloom BS: NSAID dosing schedule and compliance. Drug Intelligence Clin Pharm 22: 727728, 1988
  • 51
    Deyo RA, Inui TS, Sullivan B: Non-compliance with arthritis drugs: magnitude, correlates and clinical implications. J Rheumatol 8: 931936, 1981
  • 52
    Owen SG, Friesen WT, Roberts SR, Flux W: Determinants of compliance in RA patients assessed in their home environment. Br J Rheumatol 24: 313320, 1985
  • 53
    Greene JM, Winickoff RN: Cost-conscious prescribing of NSAID for adults with arthritis: a review and suggestions. Arch Intern Med 152: 19952002, 1992 444